by Raynovich Rod | May 17, 2019 | Biopharmaceuticals
Update-2…NASDAQ Rally triggers biotechs-XBI up 2.3% to $82.63 just above 2019 support level.Administration eased Huawei blocks because of trade concerns. Update -1 …11a EDT-Biotech Red Screen-Following NASDAQ. Risk-Off. The sell-off that started with...
by Raynovich Rod | May 12, 2019 | Biopharmaceuticals
Update-3 12:30 P EDT ASCO Rally seems too be kicking in.Green Screen! Update-2 5/15 10;45a EDT Gene therapy and mid-cap biopharma getting traction this am.XBI up 0.7% to $82.44. Update-1 5/14 3:30P EDT,Mid and small cap biotechs rally with NASDAQ, XBI up over 2%. Per...
by Raynovich Rod | May 5, 2019 | Biopharmaceuticals
Traders -look for a turnaround in small cap biopharma and medtech today. NAZ at 7890. 5/10 1:30p EDT….Well we know now that even biotech stocks are not immune to tariffs. Risk off. Major ETFS IBB at 104.5 and XBI near 84 are at intermediate support and off lows...
by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...
by Raynovich Rod | Apr 7, 2019 | Biopharmaceuticals
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.” See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks...
by Raynovich Rod | Mar 6, 2019 | Biopharmaceuticals
Update-3…3/11…Gene Therapy stocks go green screen! Big 5% winners: VYGR NTLA BLUE EDIT See complete list below (paste list into yahoo finance for tracking) Update-2…3/11…Market gets support from 60 Minutes-Powell comments and Gene Therapy;...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 10, 2019 | Biopharmaceuticals
Biotech Stocks Hold Despite Last Thursday’s Sell-Off All in the Technicals For Now, Large Caps Look Steady Biotech ETFs lost momentum last week but held near term support near the 20 Day moving average. Now that most companies have reported we should not expect...